Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC-XR) (1200 and 2400mg/Day) as Adjunctive Therapy in Subjects With Refractory Partial Seizures Due to Epilepsy on up to Three Concomitant Antiepileptic Medications.

Next Previous
Trial Profile

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC-XR) (1200 and 2400mg/Day) as Adjunctive Therapy in Subjects With Refractory Partial Seizures Due to Epilepsy on up to Three Concomitant Antiepileptic Medications.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Supernus Pharmaceuticals

    • Most Recent Events

    • 03 Feb 2014 Results will be published in the arch 2014 issue of Acta Neurologica Scandinavica according to a Supernus Pharmaceuticals media release. Results were also summarised in the media release.
    • 28 Apr 2012 Main efficacy and tolerability results presented at the 64th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2012 Results reporting neurological and ophthalmic adverse events presented at the 64th Annual Meeting of the American Academy of Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top